A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.

被引：0
|
作者：
Becerra, Carlos
Infante, Jeffrey R.
Garbo, Lawrence E.
Gordon, Michael S.
Smith, David A.
Braiteh, Fadi S.
Gandara, David R.
Jotte, Robert M.
Reckamp, Karen L.
Janku, Filip
Burris, Howard A.
Bellew, Kevin M.
Gardner, Olivia S.
Liu, Li
Cox, Donna S.
Peddareddigari, Vijay Gopal Reddy
Blumenschein, George R.
机构：
[1] Sammons Canc Ctr, Dallas, TX USA
[2] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[3] New York Oncol Hematol PC, Albany, NY USA
[4] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[5] Compass Oncol, Vancouver, WA USA
[6] US Oncol Res, Houston, TX USA
[7] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[8] UC Davis Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA
[9] Rocky Mt Canc Ctr, Denver, CO USA
[10] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[12] GlaxoSmithKline, Collegeville, PA USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3023
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
    Tolcher, A. W.
    Bendell, J. C.
    Papadopoulos, K. P.
    Burris, H. A., III
    Patnaik, A.
    Jones, S. F.
    Rasco, D.
    Cox, D. S.
    Durante, M.
    Bellew, K. M.
    Park, J.
    Le, N. T.
    Infante, J. R.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 58 - 64
  • [2] A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
    Bedard, Philippe
    Tabernero, Josep
    Kurzrock, Razelle
    Britten, Carolyn D.
    Stathis, Anastasios
    Manuel Perez-Garcia, Jose
    Zubel, Angela
    Le, Ngocdiep T.
    Carter, Kirsten
    Bellew, Kevin M.
    Gallarati, Chiara
    Niazi, Faiz
    Demanse, David
    De Buck, Stefan S.
    Sessa, Cristiana
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
    Anthony W. Tolcher
    Razelle Kurzrock
    Vincente Valero
    Rene Gonzalez
    Rebecca S. Heist
    Antoinette R. Tan
    Julie Means-Powell
    Theresa L. Werner
    Carlos Becerra
    Chenxi Wang
    Cathrine Leonowens
    Shanker Kalyana-Sundaram
    Joseph F. Kleha
    Jennifer Gauvin
    Anthony M. D’Amelio
    Catherine Ellis
    Nageatte Ibrahim
    Li Yan
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 673 - 683
  • [4] Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
    Tolcher, Anthony W.
    Kurzrock, Razelle
    Valero, Vincente
    Gonzalez, Rene
    Heist, Rebecca S.
    Tan, Antoinette R.
    Means-Powell, Julie
    Werner, Theresa L.
    Becerra, Carlos
    Wang, Chenxi
    Leonowens, Cathrine
    Kalyana-Sundaram, Shanker
    Kleha, Joseph F.
    Gauvin, Jennifer
    D'Amelio, Anthony M.
    Ellis, Catherine
    Ibrahim, Nageatte
    Yan, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (04) : 673 - 683
  • [5] A phase I/I b study of GSK1120212 (trametinib) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
    Kurata, Takayasu
    Furuse, Junji
    Okamoto, Isamu
    Kasuga, Akiyoshi
    Fujisaka, Yasuhito
    Kitamura, Hiroshi
    Shimizu, Toshio
    Takasu, Atsuko
    Okamoto, Wataru
    Naruge, Daisuke
    Nagashima, Fumio
    Katsura, Koichi
    Mukaiyama, Akihira
    Matsushita, Hideki
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
    Blumenschein, G. R., Jr.
    Smit, E. F.
    Planchard, D.
    Kim, D. -W.
    Cadranel, J.
    De Pas, T.
    Dunphy, F.
    Udud, K.
    Ahn, M. -J.
    Hanna, N. H.
    Kim, J. -H.
    Mazieres, J.
    Kim, S. -W.
    Baas, P.
    Rappold, E.
    Redhu, S.
    Puski, A.
    Wu, F. S.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 894 - 901
  • [7] A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
    Bedard, Philippe L.
    Tabernero, Josep
    Janku, Filip
    Wainberg, Zev A.
    Paz-Ares, Luis
    Vansteenkiste, Johan
    Van Cutsem, Eric
    Perez-Garcia, Jose
    Stathis, Anastasios
    Britten, Carolyn D.
    Le, Ngocdiep
    Carter, Kirsten
    Demanse, David
    Csonka, Denes
    Peters, Malte
    Zubel, Angela
    Nauwelaerts, Heidi
    Sessa, Cristiana
    CLINICAL CANCER RESEARCH, 2015, 21 (04) : 730 - 738
  • [8] A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer
    Ahmed, Shabina Roohi
    Azad, Nilofer Saba
    Ball, Douglas Wilmot
    Rudek, Michelle A.
    Nelkin, Barry
    Cosgrove, David
    Gong, Jing
    Finkelstein, Daniel
    Zahurak, Marianna
    Janku, Filip
    Downs, Melinda
    O'Connor, Ashley
    Markus, Susan
    Carducci, Michael Anthony
    Sherman, Steven I.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
    Kelly, Karen
    Mazieres, Julien
    Leighl, Natasha B.
    Barlesi, Fabrice
    Zalcman, Gerard
    Gordon, Michael S.
    Reckamp, Karen L.
    Gandara, David R.
    Gomez-Roca, Carlos Alberto
    Bennouna, Jaafar
    Cho, Byoung Chul
    Park, Keunchil
    Infante, Jeffrey R.
    Richards, Donald A.
    Wu, Yuehui
    Schramek, Daniel J.
    Cox, Donna S.
    Gardner, Olivia S.
    Peddareddigari, Vijay Gopal Reddy
    Blumenschein, George R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
    Gandara, David R.
    Hiret, Sandrine
    Blumenschein, George R.
    Barlesi, Fabrice
    Delord, Jean-Pierre
    Madelaine, Jeannick
    Infante, Jeffrey R.
    Reckamp, Karen L.
    Lara, Primo
    Audebert, Christine
    Cho, Byoung Chul
    Park, Keunchil
    Braiteh, Fadi S.
    Jotte, Robert M.
    Wu, Yuehui
    Schramek, Daniel J.
    Piepszak, Alexandra M.
    Gardner, Olivia S.
    Peddareddigari, Vijay Gopal Reddy
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345